Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR2 | O43614 | 16/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | HCRTR1 | O43613 | 4/20 | 0.48 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.45 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1037002 | 0.88 | HCRTR2 (0.62) | HCRTR2ALDH1A1HCRTR1KEAP1NFE2L2 | |
| SCHEMBL1037275 | 0.82 | HCRTR2 (0.72) | HCRTR2ALDH1A1HCRTR1KEAP1NFE2L2 | |
| SCHEMBL8339096 | 0.79 | HCRTR2 (0.77) | HCRTR2ALDH1A1HCRTR1KEAP1NFE2L2 | |
| SCHEMBL1040574 | 0.78 | HCRTR2 (0.65) | HCRTR2ALDH1A1HCRTR1KEAP1NFE2L2 | |
| SCHEMBL1038273 | 0.78 | HCRTR2 (1.00) | HCRTR2ALDH1A1HCRTR1KEAP1NFE2L2 | |
| SCHEMBL1041090 | 0.76 | HCRTR2 (1.00) | HCRTR2ALDH1A1HCRTR1KEAP1NFE2L2 | |
| SCHEMBL5001908 | 0.75 | HCRTR2 (1.00) | HCRTR2ALDH1A1HCRTR1KEAP1NFE2L2 | |
| SCHEMBL1039401 | 0.75 | HCRTR2 (0.74) | HCRTR2ALDH1A1HCRTR1KEAP1NFE2L2 | |
| SCHEMBL1040488 | 0.75 | HCRTR2 (1.00) | HCRTR2ALDH1A1KEAP1NFE2L2 | |
| SCHEMBL1039054 | 0.75 | HCRTR2 (0.77) | HCRTR2ALDH1A1KEAP1NFE2L2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2004033418-A2 | SULFONYLAMINO-ACETIC DERIVATIVES AND THEIR USE AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD. (CH) | 2004-04-22 | — | — | WO | disclosed |